Schwab Charles Investment Management Inc. Acquires 470,850 Shares of Merck & Co., Inc. (MRK)

Schwab Charles Investment Management Inc. raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 4.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 11,080,686 shares of the company’s stock after purchasing an additional 470,850 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $672,598,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Cobblestone Capital Advisors LLC NY boosted its position in shares of Merck & Co., Inc. by 0.4% in the second quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock worth $11,356,000 after acquiring an additional 774 shares during the last quarter. Associated Banc Corp lifted its position in Merck & Co., Inc. by 0.3% during the second quarter. Associated Banc Corp now owns 251,933 shares of the company’s stock valued at $15,293,000 after buying an additional 776 shares in the last quarter. Checchi Capital Advisers LLC lifted its position in Merck & Co., Inc. by 3.0% during the second quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock valued at $1,634,000 after buying an additional 792 shares in the last quarter. Mckinley Capital Management LLC Delaware lifted its position in Merck & Co., Inc. by 5.6% during the second quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock valued at $938,000 after buying an additional 815 shares in the last quarter. Finally, Brick & Kyle Associates lifted its position in Merck & Co., Inc. by 1.7% during the second quarter. Brick & Kyle Associates now owns 50,020 shares of the company’s stock valued at $3,036,000 after buying an additional 830 shares in the last quarter. Hedge funds and other institutional investors own 72.14% of the company’s stock.

Shares of NYSE:MRK opened at $70.78 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. The firm has a market capitalization of $191.70 billion, a P/E ratio of 17.78, a P/E/G ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a 12-month low of $52.83 and a 12-month high of $71.57.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.03. The business had revenue of $10.47 billion during the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.01 earnings per share. equities research analysts predict that Merck & Co., Inc. will post 4.27 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be paid a $0.48 dividend. The ex-dividend date is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.71%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.24%.

In related news, EVP Adam H. Schechter sold 107,360 shares of Merck & Co., Inc. stock in a transaction on Monday, September 17th. The shares were sold at an average price of $70.18, for a total value of $7,534,524.80. Following the completion of the sale, the executive vice president now owns 100,000 shares in the company, valued at $7,018,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sanat Chattopadhyay sold 29,208 shares of Merck & Co., Inc. stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the completion of the sale, the insider now owns 70,675 shares of the company’s stock, valued at approximately $4,608,010. The disclosure for this sale can be found here. In the last 90 days, insiders sold 649,510 shares of company stock valued at $44,201,809. Insiders own 0.32% of the company’s stock.

A number of brokerages have weighed in on MRK. Zacks Investment Research cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, June 18th. Barclays lifted their price objective on shares of Merck & Co., Inc. from $70.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, September 7th. SunTrust Banks reiterated a “buy” rating and set a $77.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. TheStreet upgraded shares of Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research note on Friday, June 8th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $70.00 price objective on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $67.93.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply